Supreme Court Takes Suo Motu Action on Exorbitant Pricing of Patented Cancer Drugs in Kerala

The Supreme Court on 17 July 2026 intervened in a case concerning the affordability of life‑saving medicines for a breast‑cancer patient from Kerala. The bench, led by Chief Justice Surya Kant and Justices Joymalya Bagchi and V Mohana, took suo motu cognisance of the issue. Key Developments The case originated in 2022 when a woman from Ernakulam filed a petition in the Kerala High Court challenging the high price of patented cancer drugs. The petitioner died while the plea was pending, prompting the High Court to continue the matter suo motu, renaming it ‘In Re Exorbitant Pricing of Life Saving Patented Medicines’. The Supreme Court issued notice and directed the Chief Justice of Kerala High Court to ensure a speedy disposal of the matter. The bench highlighted the link between the right to life and access to affordable medicines. Important Facts • The patient’s plea was filed in 2022, and she passed away before the High Court could deliver a judgment. • The Supreme Court’s intervention is based on its power to act suo motu when a matter affects public interest. • The dispute centres on patented cancer drugs , which are essential for treatment but are priced beyond the reach of many patients. • The Constitution guarantees the right to life , which courts interpret to include health care services. UPSC Relevance Understanding this case helps aspirants grasp the intersection of law, health policy, and economics. It illustrates how the judiciary can influence public health by enforcing constitutional rights and checking monopolistic pricing. The issue also touches upon intellectual property rights, drug pricing regulation, and the role of state versus central mechanisms in ensuring affordable health care – topics frequently asked in GS 2 (Polity) and GS 3 (Economy). Way Forward • The Kerala High Court is expected to expedite its decision, possibly directing price control measures or encouraging generic alternatives. • The central government may consider invoking the National Pharmaceutical Pricing Authority to regulate patented drug prices. • Continued judicial scrutiny could set precedents for future cases where essential medicines are priced prohibitively, reinforcing the link between the right to life and health equity.